Low-dose cancer medicine for children with sarcoma at high risk
Treatments studied
Part of Cancer clinical trials.
This early-phase study tests a continuous, low-dose (“metronomic”) cancer medicine to help delay cancer coming back in children and young adults with certain sarcomas. You must have finished first-line treatment and currently be in remission, starting the study soon after treatment ends.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be one of these: rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, or another soft tissue sarcoma
- Your cancer must be in remission right now (not relapsed or refractory, and no new second cancer)
- You must have finished the first/main treatment, and start this study within 6 weeks after that
- You must be fully recovered from prior treatment side effects and be well enough to do daily activities (score of 50 or higher)
- You must meet recent blood, kidney, and liver test limits (including enough platelets, white blood cells, and red blood cells)
- If you recently had surgery, you must have waited long enough to recover (at least 7 days for minor, 28 days for major surgery)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether sirolimus combined with low-dose (“metronomic”) chemotherapy can help children and young adults with certain high-risk solid tumors stay in remission or reduce recurrence risk. It is designed for people whose cancer has responded well to initial treatment, with only minimal or no visible disease on scans.
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
This study tests a combination of chemo medicines (gemcitabine, doxorubicin, docetaxel) plus an immunotherapy drug (nivolumab) for advanced sarcoma that can’t be removed with surgery. It may help shrink tumors and slow disease growth in people whose cancer has already been treated and is measurable on scans.
This Phase 2 study tests a combination treatment for locally advanced or metastatic sarcoma that cannot be fully removed by surgery. It aims to shrink tumors and control disease by combining an injected cancer-killing medicine with two cancer-fighting drugs.
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and bevacizumab) for people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. The goal is to see if this combination can help when other treatments have stopped working.
This trial uses lab-grown tumor samples from your child to test which chemotherapy drugs work best for their specific cancer. The goal is to find the most effective treatment by testing medicines on their tumor cells before giving them to your child.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.